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Human immunodeficiency virus (HIV) possesses a major threat to the human life largely due to the unavailability of an efficacious
vaccine and poor access to the antiretroviral drugs against this deadly virus. High mutation rate in the viral genome underlying the
antigenic variability of the viral proteome is the major hindrance as far as the antibody based vaccine development is concerned.
Although the exact mechanism by which CTL epitopes and the restricting HLA alleles mediate their action towards slow disease
progression is still not clear, the important CTL restricted epitopes for controlling viral infections can be utilized in future vaccine
design. This study was designed for the characterization the HIV-1 optimal CTL epitopes and their corresponding HLA alleles.
CTL epitope cluster distribution analysis revealed only two HIV-1 proteins, namely, Nef and Gag, which have significant cluster
formingcapacity.WehavefoundtheroleofspecificHLAsupertypessuchasHLAB
∗07,HLAB
∗58,andHLAA
∗03inselectingthe
hydrophobic and conserved amino acid positions within Nef and Gag proteins, to be presented as epitopes. The analyses revealed
that the clusters of optimal epitopes for Nef and p24 proteins of HIV-1 could potentially serve as a source of vaccine.
1. Introduction
Human immunodeficiency virus (HIV), a retrovirus that
belongs to the Lentiviridae family, is the causative agent of
acquiredimmunodeficiencysyndrome(AIDS).HIVgenome
is composed of 9.8Kb positive-sense, single-stranded RNA
which is reverse transcribed by the enzyme reverse tran-
scriptase to viral DNA upon its entry into the host cell [1].
Between the two types of HIV (HIV-1 and HIV-2), HIV-
1 is more virulent and responsible for most of the HIV
infections globally. Human immunodeficiency virus-1 (HIV-
1)hasinfectedmorethan60millionpeopleandcausednearly
30 million deaths worldwide [2]. In Asia, an estimated 4.9
million people were living with HIV in 2009, about the same
as5yearsearlier.MostnationalHIVepidemicsappeartohave
stabilized. Incidence fell by more than 25% in India, Nepal,
andThailandbetween2001and2009.Theepidemicremained
stable in Malaysia and Sri Lanka during this time period.
Incidence increased by 25% in Bangladesh and Philippines
between2001and2009evenasthecountriescontinuetohave
relatively low epidemic levels [3]. Although the antiretroviral
therapy has proven to be effective in controlling the infection
in the developed world, only one-fourth populations in the
developing world can afford these medications due to less
accessibility. Consequently vast majority of people are living
with a constant threat of HIV infection and death by AIDS.
In this devastating situation of world AIDS epidemic, there
is an urgent need of developing effective HIV vaccine as no
vaccine is proved to be efficacious to control HIV infection.
Tocombatthisdeadlyvirus,itsgenome,proteome,pathogen-
esis, and mechanisms of evasion of immune response should
b es t u d i e di ng r e a td e t a i l .
HIV possesses complex RNA genome and contains nine
genes which can be classified into 3 functional groups.
Among these genes, Gag, Pol, and Env are structural genes,
Tat and Rev are regulatory genes, whereas the rest of the
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genes (Vpu, Vpr, Vif, and Nef) fall into the accessory category
of genes [4]. Early HIV replication cycle begins with the
recognition of the target cells (mainly CD4
+ Tc e l l s )b yt h e
mature virion and continues as virion core particles enters
and facilitates its integration to the genomic DNA of the
chromosome of the host cell. The late phase begins with the
regulatedexpressionoftheintegratedproviralgenesandends
up with virus budding and maturation.
Gag gene encodes for 3 proteins: matrix (p17), capsid
(p24),andnucleocapsid(p7)whicharetranslatedaspolypro-
teins and later undergo a cleavage at specific site to give
rise to three individual proteins. Pol gene also encodes for a
polyprotein which has similar fate like Gag-poly-protein as it
is also cleaved by viral protease into three different proteins:
reverse transcriptase, protease, and integrase, whereas the
Env gene encodes for a single glycoprotein (gp160) which
later is cleaved into two proteins: surface glycoprotein gp120
and transmembrane protein gp41. Besides these some other
r e g u l a t o r yp r o t e i n sa r ea l s oi n c l u d e di nt h eH I Vp r o t e o m e
such as Nef, Vpr, Tat, and Ref. In Table 1,w eh a v ec o l l e c t e d
functions of HIV proteins from Uniprot database of HIV,
http://www.uniprot.org/uniprot/P04585.
High antigenic variability that results from the high
mutation rate can be considered as the characteristic features
of retrovirus such as HIV. This vast genetic heterogeneity of
HIV not only helps the virus to evade selective pressures
exerted by immune response and drug but also facilitates
the viral evolution in a faster speed [5]. Phylogenetic studies
showed the presence of three distinct groups: M (Major),
O (Outliers), and N (non-M and non-O). M is the most
predominant group of HIV-1 around the world [6]. Within
t h eMg r o u pt h e r ea r en i n es u b t y p e s :A – D ,F – H ,J ,a n dK .
Among these, subtypes B are prevalent in most regions of the
world such as USA, Europe, South East Asia, Australia, and
South Africa [6].
Endogenous pathway of antigen processing and presen-
tation is used to present endogenously synthesized cellular
peptides as well as viral protein fragments via the MHC class
I molecule to the cytotoxic-T-lymphocytes (CTLs). In this
pathway, the proteins that are destined for the presentation
are marked by the ubiquitinylation and subjected to prote-
olytic cleavage by the immunoproteasome. The fragments of
p e p t i d e sa r et r a n s p o r t e dt ol u m e no fE Rb yt h eh e l po fT A P
(TAP1 and TAP2). These TAP proteins also help the loading
of the short peptides with appropriate length (9 amino acids)
into the groove of MHC class I molecule [7]. Although
proteasome is the main player in generating the bulk of the
CTLepitopes,cytosolicendopeptidasesmayalsobeinvolved
in the production of certain CTL epitopes [8].
Peptides are typically tightly associated along their entire
l e n g t hi nM H Cc l a s sIg r o o v e .Th eNa n dCt e r m i n io ft h e
pe p ti d ea r efi rml yH - bo n d edt oth ec o n se rv edr e s i d u e so fth e
MHCgroove.Theanalysisofthenaturallyoccurringpeptides
extractedfromtheMHC-peptidecomplexrevealedthatthese
a r em o s t l y8 - 9r e s i d u e sl o n ga n di nc e r t a i nk e yp o s i t i o n s
amino acids tend to be conserved within the peptide. These
are called anchor positions which are proved to be essential
for the binding of peptides to MHC class I molecules in allele
specific manner. There are typically two (sometimes three)
m a j o ra n c h o rp o s i t i o n sf o rt h ec l a s sIb i n d i n gp e p t i d e s .O n e
is located at the C terminal end and the other one usually lies
in the position 2 (P2) but also occurs in P3, 5, or 7 [7].
Cytotoxic-T-lymphocytes (CTLs) are one of the vital
components of cellular immunity and play crucial role in
eliminating viral infection. CTLs recognize viral antigen on
thesurfaceofvirallyinfectedcellsincombinationwithappro-
priate major histocompatibility complex (MHC) molecule
and exert their effect by killing the infected cells either by
lysis or inducing apoptosis. Previous studies suggested that
the HIV infection process can be divided into 3 stages. These
a r e( 1 )a c u t ev i r e m i a ,( 2 )al a t e n c yp e r i o do fv a r i a b l et i m e
period,and(3)clinicalAIDS.AtthelaterstagesofHIVinfec-
tion CD4
+ T cells counts drops down below 200cells/mm
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which causes the complete collapse of immune response
and consequently the opportunistic infectious agents such
as Pneumocystis carinii come into the play [9]. There is now
increasingbodyofevidencethatCTLsplayanimportantrole
in controlling the HIV infection. Analysis of the immune
responses of the HIV infected patients revealed that antiviral
CTL activity is correlated with clearance of virus particles
d u r i n gt h ea c u t ep h a s eo fi n f e c t i o na n dad e c l i n ei nt h eC T L
activityisassociatedwiththediseaseprogression[9,10].Two
types of antiviral CTL responses have been documented so
far: one is classical viral epitope dependent-MHC restricted
killin go fvirall yinf ect edce ll sa n dth eo th ero n ei sth en o n cy-
tolytic response in which CTLs control the viral infection by
inhibiting the viral replication [11]. Furthermore, studies of
theSIV-macaquemodel,inwhichtheadministrationofanti-
CD8 monoclonal antibodies hinders the decline in viremia,
provided strong evidence for the crucial role of CTLs in
controlling HIV infection during acute phase [12]. Recently
Goulder and Watkins have suggested three additional lines
of evidence which signifies the potential role of CTLs in
suppressing HIV infection: first they argued that specific
HLA class I molecules are consistently associated with par-
ticular HIV disease outcomes. Secondly, they highlighted
t h ef a c tt h a tm o r er a p i dd i s e a s ep r o g r e s s i o ni so b s e r v e di n
individuals with HLA class I homozygosity, and lastly they
provided evidence that the loss of immune control over
HIV infection arises when viral mutants escape CD8
+ T-cell
recognition [13]. All the above mentioned evidence signifies
the important antagonizing role of CTL immune response in
HIV disease progression.
2. Analysis of the HLA Class I Restricted CTL
Epitopes in HIV Proteome
Design and development of HIV vaccine largely depend
on our understanding of complex dynamics between host
immune response and viral adaptation to selective pressure
exerted by the host. Understanding how the CTL epitopes
interact with particular HLA alleles can give an insight
into the mechanisms of success or failure of immune
control of a pathogen, such as HIV-1, for which clearance
of virus particles depends on CTL activity. So the vaccine
development strategies for HIV should be focused on
identifying the epitopes presented by HLA alleles prevalentAdvances in Virology 3
Table 1: Function of different HIV proteins.
Protein Precursor Functions
P17 Gag
Matrix protein p17 has two main functions. Firstly it targets Gag-pol polyproteins to the plasma membrane by
the help of a membrane-binding signal which contains myristoylated N-terminus. Secondly it plays an essential
role in the nuclear localization of the viral genome.
P24 Gag Protein p24 forms the nucleocapsid that encapsulates the viral genomic RNA in the virion. The core is
disassembled immediately after the entry of virion into host cell.
P7 Gag
Nucleocapsid protein p7 encapsulates viral genomic RNA and hence provides protection to viral genome. It
binds these RNAs through its zinc finger motifs. It also acts as a nucleic acid chaperone as it tends to facilitate
the rearrangement of nucleic acid secondary structure during reverse transcription of genomic RNA.
RT Gag-pol
Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that facilitates the reverse transcription
of viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme also
displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase
H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes.
Integrase Gag-pol Integrase catalyzes integration of viral DNA into the host chromosome, by a multistep process involving DNA
cutting and joining reactions.
Protease Gag-pol Cleavage of viral precursor polyproteins into mature proteins
Gp120 GP160
The surface protein gp120 (SU) facilitates the anchoring of the virus to the host target cell (CD4+) by binding to
the primary receptor CD4. This interaction induces a change in the conformation exposing a high affinity
binding site for a chemokine coreceptor (CXCR4 and/or CCR5) and promotes subsequent interaction between
the envelope protein and CXCR4 and/or CCR5.
Tat
Tat acts as a nuclear transcriptional activator of viral gene expression that is essential for viral transcription
from the LTR promoter. It also directs the components of the cellular transcription machinery into the viral
RNA to promote transcription by the RNA polymerase complex.
Vif It ensures the downregulation of APOBEC3G by recruiting the ubiquitin-proteasome machinery that targets
APOBEC3G for degradation. It also binds to viral RNA and affects the stability of viral nucleoprotein core.
Vpr
It is largely involved in the transport of the viral preintegration (PIC) complex to the nucleus during the early
phase of the infection. It probably interacts with karyopherin alpha/KPNA1 and KPNA2 thereby increasing
their affinity for basic-type nuclear localization signal harboring proteins such as viral matrix protein, thus
facilitating the translocation of the viral proteins into the nucleus.
Vpu
It promotes virion budding, by targeting human CD4 and CD317 to proteasomal degradation. CD4 degradation
hinders any possible interactions between viral Env and human CD4 in the endoplasmic reticulum. It helps the
proper Env assembly into virions.
Nef
(1) Downregulation of surface MHC-I molecules.
(2) Downregulation of cell surface CD4 antigen. It interacts with the Src family kinase LCK and induces
LCK-CD4 dissociation. Subsequently it causes clathrin-dependent endocytosis of CD4 antigen. Ultimately, the
CD4 are decreased and infected cells.
(3) It decreases the number of viral receptors and hence prevents reinfection by more HIV particles.
(4) It prevents the apoptosis of the infected cell by inhibiting the Fas and TNFR-mediated death signals. It also
interacts with p53 and protects the infected cell against p53-mediated apoptosis. Furthermore, it regulates the
Bcl-2 family proteins through the formation of a Nef/PI3-kinase/PAK2 complex that induces phosphorylation
of Bad.
in populations severely affected by the global HIV epidemic.
In recent years, development of new technologies such as
measuring interferon-gamma (IFN𝗾)r e l e a s eb yt h ee n z y m e
linked immunospot (ELISPOT) assay and flow cytometry
ensuredtheefficientevaluationofCTLresponsesagainstHIV
epitopes [14]. Moreover, development of overlapping pooled
p e p t i d et e c h n o l o g y( O L P )n o wp r o v i d e st h eo p p o r t u n i t yf o r
the detailed and precise analyses of HIV-1-specific cellular
immune responses by elucidation of the T-cell epitopes and
the identification of immunodominant regions of HIV-1
gene products. Identification and characterization of the
CTL epitopes as well as the corresponding HLA alleles can
play a major role in elucidating the nature of protective
CTL response and mechanism of the immune evasion
of HIV. A large number of HIV CTL epitopes have been
identified and deposited into various databases. Apart from
the experimental methods, various computational tools are
now available which can predict CTL epitopes within viral
proteome by using different sets of algorithms, for example,
artificial neural network (ANN), average relative binding
(ARB), stabilized matrix method (SMM), and so forth. The
first CTL epitope was identified in 1988 by using synthetic
peptide technology [15]. Since then, over 1200 HLA class I
restricted HIV-1 epitopes were identified in HIV proteome
(http://www.hiv.lanl.gov/content/immunology/index.html).
In Table 2, a list of HLA class I allele restricted optimal
CTL epitopes for HIV along with their corresponding HLA
alleles and clades is given. For the identification of optimal
epitopes,twocriteriawereimposedasdescribedbyLlanoaet
al. [16]. These criteria include the unequivocal experimental4 Advances in Virology
Table 2: List of optimal CTL epitopes for HIV-1 (taken and modified from HIV molecular immunology database
(http://www.hiv.lanl.gov/content/immunology/tables/optimal ctl summary.html).
HIV protein AA position HLA Sequence Clade
gp160 2–10 B
∗0801 (B8) RVKEKYQHL —
gp160 31–39 B
∗1801 (B18) AENLWVTVY B
gp160 31–39 B44 AENLWVTVY B
gp160 31–40 B
∗4402 (B44) AENLWVTVYY —
gp160 37–46 A
∗0301 (A3) TVYYGVPVWK A, B, C, D
gp160 42–51 B
∗5501 (B55) VPVWKEATTT —
gp160 42–52 B
∗3501 (B35) VPVWKEATTTL B
gp160 52–61 A
∗2402 (A24) LFCASDAKAY —
gp160 59–69 B58 KAYETEVHNVW C
gp160 61–69 B
∗1801 (B18) YETEVHNVW B
gp160 78–86 B
∗3501 (B35) DPNPQEVVL B
gp160 104–112 B
∗3801 (B38) MHEDIISLW B
gp160 199–207 A
∗1101 (A11) SVITQACPK B
gp160 209–217 A
∗2902 (A29) SFEPIPIHY B, D
gp160 298–307 B
∗0702 (B7) RPNNNTRKSI B, C
gp160 310–318 A
∗3002 (A30) HIGPGRAFY B
gp160 311–320 A
∗0201 (A2) RGPGRAFVTI A, B, C
gp160 375–383 B
∗1516 (B63) SFNCGGEFF A, B, C
gp160 375–383 Cw
∗0401 (Cw4) SFNCGGEFF A, B, C
gp160 416–424 B
∗5101 (B51) LPCRIKQII B
gp160 419–427 A
∗3201 (A32) RIKQIINMW B, C
gp160 511–519 Cw18 YRLGVGALI C
gp160 557–565 Cw
∗0304 (Cw10) RAIEAQQHL A, B, C, D
gp160 557–565 Cw8 RAIEAQQHM A, B, C, D
gp160 557–565 Cw15 RAIEAQQHL C
gp160 584–592 B
∗1402 (B14) ERYLKDQQL A, B, C, D
gp160 585–593 A23 RYLKDQQLL B, C
gp160 585–593 A
∗2402 (A24) RYLKDQQLL B, C
gp160 586–593 B
∗0801 (B8) YLKDQQLL A, B
gp160 606–614 B
∗3501 (B35) TAVPWNASW B
gp160 698–707 A
∗3303 (A33) VFAVLSIVNR B
gp160 703–712 A
∗2501 (A25) EIIFDIRQAY —
gp160 704–712 A
∗3002 (A30) IVNRNRQGY B
gp160 770–780 A
∗0301 (A3) RLRDLLLIVTR B, C
gp160 770–780 A
∗3101 (A31) RLRDLLLIVTR B, C
gp160 777–785 A
∗6802 (A68) IVTRIVELL B
gp160 786–795 B
∗2705 (B27) GRRGWEALKY B
gp160 787–795 A
∗0101 (A1) RRGWEVLKY B
gp160 794–802 A
∗3002 (A30) KYCWNLLQY B
gp160 805–814 B
∗4001 (B60) QELKNSAVSL B
gp160 813–822 A
∗0201 (A2) SLLNATDIAV B
gp160 831–838 A
∗3303 (A33) EVAQRAYR B
gp160 843–851 B
∗0702 (B7) IPRRIRQGL A, B, C, D
gp160 846–854 A
∗0205 (A2) RIRQGLERA B
gp160 848–856 B8 RQGLERALL —
Integrase 28–36 B42 LPPIVAKEI B, C
Integrase 66–74 B
∗1510 (B71) THLEGKIIL B, CAdvances in Virology 5
Table 2: Continued.
HIV protein AA position HLA Sequence Clade
Integrase 123–132 B57 STTVKAACWW B
Integrase 135–143 B
∗1503 (B72) IQQEFGIPY B, C
Integrase 165–172 Cw18 VRDQAEHL C
Integrase 173–181 B
∗5701 (B57) KTAVQMAVF B
Integrase 179–188 A
∗0301 (A3) AVFIHNFKRK B, multiple
Integrase 179–188 A
∗1101 (A11) AVFIHNFKRK B, multiple
Integrase 185–194 B
∗1503 (B72) FKRKGGIGGY B, C
Integrase 203–211 A
∗1101 (A11) IIATDIQTK B
Integrase 219–227 A
∗3002 (A30) KIQNFRVYY AE, B, C, D
Integrase 260–268 B42 VPRRKAKII —
Integrase 263–271 B
∗1503 (B72) RKAKIIRDY B, C
Nef 13–20 B
∗0801 (B8) WPTVRERM B
Nef 19–27 B62 RMRRAEPAA B
Nef 37–45 B
∗4001 (B60) LEKHGAITS B
Nef 37–45 B50 LEKHGAITS B
Nef 68–76 B
∗0702 (B7) FPVTPQVPL B
Nef 68–77 B
∗0702 (B7) FPVTPQVPLR B
Nef 71–79 B
∗0702 (B7) TPQVPLRPM B
Nef 71–79 B
∗4201 (B42) RPQVPLRPM B, C
Nef 73–82 A
∗0301 (A3) QVPLRPMTYK A, B, C, D
Nef 73–82 A
∗1101 (A11) QVPLRPMTYK A, B, C, D
Nef 74–81 B
∗3501 (B35) VPLRPMTY A, B, C, D
Nef 75–82 A
∗1101 (A11) PLRPMTYK B
Nef 77–85 B
∗0702 (B7) RPMTYKAAL B
Nef 82–91 Cw8 KAAVDLSHFL B
Nef 83–91 A
∗0205 (A2) GAFDLSFFL A
Nef 83–91 Cw3 AALDLSHFL B
Nef 83–91 Cw
∗0802 (Cw8) AAVDLSHFL B, C
Nef 84–92 A
∗0301 (A3) AVDLSHFLK A, B, D, F
Nef 84–92 A
∗1101 (A11) AVDLSHFLK A, B, D, F
Nef 90–97 B
∗0801 (B8) FLKEKGGL A, B, C, D
Nef 92–100 B
∗4001 (B60) KEKGGLEGL B, C
Nef 92–100 B
∗4002 (B61) KEKGGLEGL B, C
Nef 105–114 B
∗2705 (B27) RRQDILDLWI B
Nef 105–115 B18 RRQDILDLWVY B
Nef 105–115 Cw7 KRQEILDLWVY B, C
Nef 106–114 B13 RQDILDLWI B
Nef 106–115 B
∗0702 (B7) RQDILDLWIY —
Nef 116–124 B57 HTQGYFPDW B, C
Nef 116–125 B
∗5701 (B57) HTQGYFPDWQ B, C
Nef 117–127 B
∗1501 (B62) TQGYFPDWQNY B, C
Nef 120–128 A29 YFPDWQNYT B, C
Nef 120–128 B
∗3701 (B37) YFPDWQNYT B, C
Nef 120–128 B
∗5701 (B57) YFPDWQNYT B, C
Nef 120–128 Cw6 YFPDWQNYT B, C
Nef 127–135 B57 YTPGPGIRY B, C
Nef 127–135 B63 YTPGPGIRY B, C
Nef 128–137 B
∗0702 (B7) TPGPGVRYPL B, C6 Advances in Virology
Table 2: Continued.
HIV protein AA position HLA Sequence Clade
Nef 128–137 B
∗4201 (B42) TPGPGVRYPL B, C
Nef 133–141 A33 TRYPLTFGW B
Nef 134–141 A
∗2402 (A24) RYPLTFGW B, C
Nef 135–143 B
∗1801 (B18) YPLTFGWCY B, C, D
Nef 135–143 B53 YPLTFGWCF B
Nef 135–143 B
∗5301 (B53) YPLTFGWCY B
Nef 136–145 A
∗0201 (A2) PLTFGWCYKL B
Nef 137–145 B57 LTFGWCFKL A, B, C
Nef 137–145 B63 LTFGWCFKL A, B, C
Nef 180–189 A
∗0201 (A2) VLEWRFDSRL B
Nef 183–191 B
∗1503 (B72) WRFDSRLAF B
p17 11–19 B
∗4002 (B61) GELDRWEKI B
p17 18–26 A
∗0301 (A3) KIRLRPGGK A, B
p17 19–27 B
∗2705 (B27) IRLRPGGKK B
p17 20–28 A
∗0301 (A3) RLRPGGKKK A, B
p17 20–29 A
∗0301 (A3) RLRPGGKKKY B
p17 24–32 B
∗0801 (B8) GGKKKYKLK B, F
p17 28–36 A
∗2402 (A24) KYKLKHIVW B, C, F
p17 33–41 Cw
∗0804 (Cw8) HLVWASREL C
p17 34–44 A30 LVWASRELERF B, C
p17 36–44 B
∗3501 (B35) WASRELERF B, C
p17 74–82 B
∗0801 (B8) ELRSLYNTV F
p17 76–86 A
∗3002 (A30) RSLYNTVATLY B, C, F
p17 76–86 B58 RSLYNTVATLY B, C, F
p17 76–86 B63 RSLYNTVATLY B, C, F
p17 77–85 A
∗0 2 0 1( A 2 ) S L Y N TV A T L A ,B ,C ,D ,F ,G ,K
p17 77–85 A
∗0 2 0 2( A 2 ) S L Y N TV A T L A ,B ,C ,D ,F ,G ,K
p17 77–85 A
∗0 2 0 5( A 2 ) S L Y N TV A T L A ,B ,C ,D ,F ,G ,K
p17 78–85 Cw14 LYNTVATL B, D
p17 78–86 A
∗2902 (A29) LYNTVATLY B, C
p17 78–86 B
∗4403 (B44) LYNTVATLY B, C
p17 84–91 A
∗1101 (A11) TLYCVHQK —
p17 92–101 B
∗4001 (B60) IEIKDTKEAL B, F
p17 124–132 B
∗3501 (B35) NSSKVSQNY B
p24 3–11 B13 VQNLQGQMV B, C
p24 12–20 B
∗1510 (B71) HQAISPRTL B
p24 13–23 A
∗2501 (A25) QAISPRTLNAW B
p24 15–23 B
∗5701 (B57) ISPRTLNAW A, C
p24 15–23 B63 ISPRTLNAW A, B, C, D
p24 16–24 B
∗0702 (B7) SPRTLNAWV B
p24 24–32 B
∗1503 (B72) VKVIEEKAF B, C
p24 28–36 B
∗4415 (B12) EEKAFSPEV A, B, C, D
p24 30–37 B
∗5703 (B57) KAFSPEVI B
p24 30–40 B
∗5 7 0 1( B 5 7 ) K A F S P E V I P M F A ,B ,C ,G
p24 30–40 B
∗5 7 0 3( B 5 7 ) K A F S P E V I P M F A ,B ,C ,G
p24 30–40 B63 KAFSPEVIPMF A, B, C, G
p24 32–40 B57 FSPEVIPMF B, C
p24 35–43 A
∗2601 (A26) EVIPMFSAL A, B, C, DAdvances in Virology 7
Table 2: Continued.
HIV protein AA position HLA Sequence Clade
p24 36–43 Cw
∗0102 (Cw1) VIPMFSAL B, D
p24 44–52 B
∗4001 (B60) SEGATPQDL B
p24 48–56 B
∗0702 (B7) TPQDLNTML A, B, C, D
p24 48–56 B
∗3910 (B39) TPQDLNTML A, B, C, D
p24 48–56 B
∗4201 (B42) TPQDLNTML A, B, C, D
p24 48–56 B
∗5301 (B53) TPYDINQML A
p24 48–56 B
∗8101 (B81) TPQDLNTML A, B, C, D
p24 48–56 Cw
∗0802 (Cw8) TPQDLNTML A, B, C, D
p24 61–69 B
∗1510 (B71) GHQAAMQML B, C
p24 61–69 B
∗3901 (B39) GHQAAMQML B, C
p24 70–78 B
∗4002 (B61) KETINEEAA B
p24 71–80 A
∗2501 (A25) ETINEEAAEW A, B, D
p24 78–86 B
∗4002 (B61) AEWDRVHPV B
p24 84–92 B7 HPVHAGPIA B, C, D, F
p24 94–104 B13 GQMREPRGSDI B, C
p24 108–117 B
∗5701 (B57) TSTLQEQIGW B, C
p24 108–117 B
∗5801 (B58) TSTLQEQIGW B, C
p24 122–130 B
∗3501 (B35) PPIPVGDIY A, B, C
p24 128–135 B
∗0801 (B8) EIYKRWII B
p24 131–140 B
∗2703 (B27) RRWIQLGLQK —
p24 131–140 B
∗2705 (B27) KRWIILGLNK A, B, C, D
p24 137–145 B
∗1501 (B62) GLNKIVRMY A, B
p24 142–150 Cw18 VRMYSPVSI B, C, F
p24 143–150 B
∗5201 (B52) RMYSPTSI B, F
p24 161–169 Cw18 FRDYVDRFF C
p24 161–170 B
∗1801 (B18) FRDYVDRFYK B, D
p24 162–172 A
∗2402 (A24) RDYVDRFFKTL A
p24 162–172 B
∗4402 (B44) RDYVDRFYKTL B, D
p24 164–172 Cw
∗0303 (Cw9) YVDRFFKTL A, C, D
p24 164–172 A
∗0207 (A2) YVDRFYKTL B
p24 164–172 B
∗1503 (B72) YVDRFFKTL A, C, D
p24 164–172 Cw
∗0304 (Cw10) YVDRFFKTL A, C, D
p24 166–174 B
∗1402 (B14) DRFYKTLRA B, D
p24 174–184 B
∗4402 (B44) AEQASQDVKNW B, C, D
p24 174–185 Cw5 AEQASQEVKNWM —
p24 176–184 B
∗5301 (B53) QASQEVKNW B, D
p24 176–184 B
∗5701 (B57) QASQEVKNW C
p24 197–205 B
∗0801 (B8) DCKTILKAL B
p24 217–227 A
∗1101 (A11) ACQGVGGPGHK B
p24 223–231 B
∗0702 (B7) GPGHKARVL B, C, D, F
Protease 3–11 A
∗6802 (A68) ITLWQRPLV A, B, C, D
Protease 3–11 A
∗7401 (A19) ITLWQRPLV A, B, C, D
Protease 30–38 A
∗6802 (A68) DTVLEEWNL D
Protease 34–42 B44 EEMNLPGRW B
Protease 57–66 B13 RQYDQILIEI B
Protease 68–76 B
∗1503 (B72) GKKAIGTVL BC
Protease 70–77 B57 KAIGTVLV BC
Protease 76–84 A
∗0201 (A2) LVGPTPVNI B8 Advances in Virology
Table 2: Continued.
HIV protein AA position HLA Sequence Clade
Protease 80–90 B81 TPVNIIGRNML C
Rev 14–23 B
∗5701 (B57) KAVRLIKFLY B
Rev 14–23 B
∗5801 (B58) KAVRLIKFLY B
Rev 14–23 B63 KAVRLIKFLY B
Rev 41–50 B7 RPAEPVPLQL A, B, C, D, F
Rev 57–66 A
∗0301 (A3) ERILSTYLGR B
Rev 67–75 Cw
∗0501 SAEPVPLQL B
RT 5–12 B
∗4001 (B60) IETVPVKL B
RT 18–26 B
∗0 8 0 1( B 8 ) G P K V K Q W P L A ,B ,C ,D
RT 33–41 A
∗0201 (A2) ALVEICTEM B
RT 33–43 A
∗0301 (A3) ALVEICTEMEK B
RT 42–50 B
∗5101 (B51) EKEGKISKI B
RT 73–82 A
∗0301 (A3) KLVDFRELNK B
RT 93–101 A
∗0301 (A3) GIPHPAGLK B
RT 107–115 B
∗3501 (B35) TVLDVGDAY AG, B
RT 118–127 B
∗3501 (B35) VPLDEDFRKY B, C
RT 127–135 A2 YTAFTIPSV —
RT 128–135 B
∗5101 (B51) TAFTIPSI B
RT 137–146 B18 NETPGIRYQY B, C
RT 142–149 B
∗1401 (B14) IRYQYNVL C
RT 156–164 B7 SPAIFQSSM A, B, C, D
RT 158–166 A
∗0301 (A3) AIFQSSMTK A, B, C, D
RT 158–166 A
∗1101 (A11) AIFQSSMTK —
RT 173–181 A
∗3002 (A30) KQNPDIVIY B
RT 175–183 B18 NPEIVIYQY C
RT 175–183 B
∗3501 (B35) HPDIVIYQY A, B
RT 179–187 A
∗0201 (A2) VIYQYMDDL A, B, C, D
RT 202–210 B
∗4001 (B60) IEELRQHLL B
RT 244–252 B
∗5701 (B57) IVLPEKDSW B
RT 260–271 B
∗1501 (B62) LVGKLNWASQIY B
RT 263–271 A
∗3002 (A30) KLNWASQIY B, C
RT 269–277 A
∗0301 (A3) QIYPGIKVR B, C
RT 271–279 B
∗4201 (B42) YPGIKVRQL B, C
RT 309–317 A
∗0201 (A2) ILKEPVHGV A, B, C, D
RT 309–318 B
∗1501 (B62) ILKEPVHGVY A, B, D
RT 333–341 B13 GQGQWTYQI B
RT 341–350 A
∗1101 (A11) IYQEPFKNLK B, C
RT 356–365 A
∗3002 (A30) RMRGAHTNDV B
RT 356–366 A
∗0301 (A3) RMRGAHTNDVK B
RT 375–383 B
∗5801 (B58) IAMESIVIW B, C
RT 392–401 A
∗3201 (A32) PIQKETWETW B
RT 436–445 A
∗6802 (A68) GAETFYVDGA B, C
RT 438–448 A66 ETFYVDGAANR B, C
RT 449–457 A
∗2601 (A26) ETKLGKAGY B
RT 495–503 Cw
∗0802 (Cw8) IVTDSQYAL —
RT 496–505 B
∗1503 (B72) VTDSQYALGI —
RT 520–528 A
∗1101 (A11) QIIEQLIKK B
RT 560–568 B81 LFLDGIDKA —Advances in Virology 9
Table 2: Continued.
HIV protein AA position HLA Sequence Clade
Tat 2–11 B
∗5301 (B53) EPVDPRLEPW B
Tat 2–11 B58 EPVDPRLEPW B
Tat 30–37 Cw12 CCFHCQVC B
Tat 38–47 B
∗1503 (B72) FQTKGLGISY C
Tat 39–49 A
∗6801 (A68) ITKGLGISYGR B
Vif 17–26 A
∗0301 (A3) RIRTWKSLVK B
Vif 28–36 A
∗0301 (A3) HMYISKKAK B
Vif 31–39 B
∗5701 (B57) ISKKAKGWF B
Vif 48–57 B
∗0702 (B7) HPRVSSEVHI B
Vif 57–66 B51 IPLGDAKLII B
Vif 79–87 B
∗1510 (B71) WHLGHVSI B
Vif 79–87 B
∗3801 (B38) WHLGQGVSI B
Vif 102–111 B
∗1801 (B18) LADQLIHLHY B
Vif 158–168 A
∗0301 (A3) KTKPPLPSVKK B
Vpr 29–37 B51 EAVRHFPRI B
Vpr 30–38 B
∗5701 (B57) AVRHFPRIW B, C
Vpr 31–39 B27 VRHFPRIWL B
Vpr 34–42 B
∗0702 (B7) FPRIWLHGL B
Vpr 34–42 B
∗8101 (B81) FPRIWLHGL B
Vpr 48–57 A
∗6802 (A68) ETYGDTWTGV C
Vpr 52–62 A
∗6801 (A68) DTWAGVEAIIR B
Vpr 59–67 A
∗0201 (A2) AIIRILQQL B
Vpu 29–37 A
∗3303 (A33) EYRKILRQR B
Gag-Pol 24–31 Cw
∗0102 (Cw1) NSPTRREL —
p2p7p1p6 1–10 B
∗4501 (B45) AEAMSQVTNS —
p2p7p1p6 42–50 B14 CRAPRKKGC B
p2p7p1p6 64–71 B
∗4002 (B61) TERQANFL B
p2p7p1p6 66–74 B13 RQANFLGKI B, C
p2p7p1p6 70–79 A
∗0201 (A2) FLGKIWPSYK B
p2p7p1p6 118–126 B
∗4001 (B60) KELYPLTSL B
validation of the epitope restriction by a specific HLA class
I allele and the definition of the optimal epitope length (8
to 10 amino acid long). Analysis of the CTL epitopes listed
in Table 2 reveals that epitopes from 5 HIV proteins (gp160,
Nef, p24, p17, and RT) contributed 77% of the total epitopes
listed in Table 2. The remaining percentage of the epitopes
was derived from the eight other HIV proteins (Integrase,
p2p7p1p6, Protease, Rev, Tat, Vpu, Vif and Vpr). The highest
number of optimal epitopes was found for p24 (54) while the
only one optimal epitope was identified for vpu (Figure 1).
The epitope number for gp160, Nef, RT, and p17 were 45,
4 3 ,4 1 ,a n d2 3 ,r e s p e c t i v e l y .Th en u m b e ro fu n i q u ea l l e l e s
recognized by these epitopes was also analyzed and found to
be correlated with number of epitopes for each HIV protein
(Figure 1). For instance, 54 p24 CTL epitopes were restricted
cumulatively by 35 unique HLA class I alleles. Similarly,
for the epitopes of gp160, Nef, p17, and RT, the numbers of
unique HLA class I alleles were found to be 31, 29, and 25,
respectively.
3. Clustering of CTL Epitopes in
HIV Proteome
Analysis of the HIV-1 proteins reveals that HLA class
I restricted epitopes form overlapping clusters known as
epitope rich/dense region whereas the regions deficient of
any epitope clusters are called the epitope poor regions [17].
Yusim et al. have identified four short overlapping clusters in
Nef protein of HIV-1 which was found to be multirestricted
indicating that the clusters contain several epitopes recog-
nized by different class I HLA molecules [18]. In another
study, Currier et al. identified CTL epitope distribution
patternsintheGagandNefproteinsofHIV-1fromsubtype-A10 Advances in Virology
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Figure 1: Number of optimal CTL epitopes and unique HLA recognized (a) and the percentage of clades (b) to which the optimal epitopes
belong for whole HIV proteome were shown.
infected subjects [19]. Studies aided with powerful exper-
imental as well as computational methods are now being
conducted with the aim to construct a fine CTL epitope map
forthewholeHIV-1proteome.Withtheadvancementofnew
sophisticatedcomputationalandstatisticalmethods,itisnow
possible to identify the epitope clusters computationally.One
significant achievement in computationalimmunology is the
methodofidentificationofimmunoproteasomecleavagesites
within the query proteins by using different algorithms such
as artificial neural network (ANN) which enables the rapid
identification of a wide range of potential epitopes that can
be analyzed both computationally and experimentally for
their affinity to bind with particular HLA class I molecules.
Studies, dedicated to identify the CTL epitope clusters by
means of computational methods, are now showing some
success as far as the identification of new epitope clusters is
concerned, as some novel epitope containing clusters were
identified. However, more developments in the algorithms
arerequiredtoconstructmorerealisticmodelsofepitopeand
cleavage site prediction, so that the predicted proteasomal
cleavageeventsobservedincalculationmaybettermimicthe
actualprocessingofviralantigensinthenaturalenvironment.
In this study, the analysis of the topological arrangement
of the 269 experimentally validated optimal epitopes in the
HIV proteins listed in Table 2 allowed the identification
of epitope clusters in the individual HIV proteins. Among
the 13 different HIV proteins (listed in Table 2), epitope
clustering was performed for 5 proteins (gp160, Nef, p17,
p24, and RT) because for these proteins a relatively higher
number of epitopes were identified (Figure 2 and Table 3).
The aim of the cluster analysis is to identify the epitope dense
regions or “hot spots” in the HIV-1 proteome. To cancel
the possibility of random matching, the clusters containing
more than 5 overlapping epitopes were only considered. For
gp160, 2 major epitope clusters can be observed where the
first (amino acid position: 31 to 69) and second (amino acid
position: 770–838) cluster harboured 9 epitopes each. Like
the gp160 protein 2 major clearly defined clusters were also
identified for the Nef and p17 protein. In case of Nef, one
spans from 68 to 100 and the second one lies between 105
and 145 amino acid positions. In previous study Penciolelli
et al. [20] identified 4 clusters in the Nef protein which falls
within the epitope cluster range for Nef observed in this
study. For p17 protein, two clusters were similar in epitope
compositionandlength.Firstp17clusterwith34aminoacids
wasfoundtocontain10epitopeswhereas2ndp17clusterwith
12 epitopes was composed of 30 amino acids. p24 was found
to contain maximum numbers (4) of major epitope clusters.
For RT only 1 major cluster was identified which contained 9
overlappingepitopes,whereastherestofepitopeswerefound
to be distributed randomly in protein.
Data from Table 3 suggest that epitopes in both the RT
and gp160 proteins did not exhibit significant clustering
properties compared to other HIV proteins. Only 40% and
22% of the epitopes were identified as part of the major
cluster in gp160 and RT, respectively, which indicated that
the majority of the epitopes were distributed randomly in
respective proteins. Epitopes from other three proteins Nef,
p17, and p24 showed significant clustering pattern as evident
by both Figure 4 and Table 3. Most of the epitopes in these
proteins were found to be a part of cluster or epitope dense
region.
4. Are the CTL Epitope Clusters Conserved and
Hydrophobic in Nature?
By analyzing the nature of the CTL epitopes and their source
proteins, Hughes and Hughes proposed two hypotheses
about the nature of the CTL epitopes. First they proposed
that the endogenous peptides presented by human leukocyte
antigen (HLA) class I molecules are largely derived fromAdvances in Virology 11
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Table 3: Analysis of the identified epitope clusters in HIV-1 proteins.
HIV-1 protein Total epitope
number Cluster number Cluster amino acid
position
Cluster length
(amino acids)
Number of
epitopes in cluster
%o fc l u s t e r e d
epitopes in total
epitope pool
Gp160 45 13 1 – 6 9 3 9 9 40
27 7 0 – 8 3 8 6 9 9
Nef 43 16 8 – 1 0 0 3 3 1 8 97
2 105–145 41 24
p17 23 11 1 – 4 4 3 4 1 0 95
27 2 – 1 0 1 3 0 1 2
p24 54
13 – 5 6 5 42 2
98 26 1 – 1 1 7 5 7 9
31 2 8 – 1 5 0 4 3 9
41 6 1 – 1 8 4 2 4 1 3
RT 41 1 107–166 60 9 22
conservedregionsofproteins,soingeneraltheCTLepitopes
tend to be more conserved than the remainder portion of
the source proteins. Secondly they hypothesized that the
CTL epitope regions are hydrophobic whereas the source
protein may itself be overall hydrophilic in nature [8]. In
harmony with these hypotheses, Silva and Hughes showed
that the CTL epitopes of HIV-1 Nef protein were derived
from the hydrophobic and relatively conserved regions by
estimating the relative conservation of CTL epitopes of the
Nef protein and relating this to the structure and function of
the protein. In another study Lucchiari-Hartz et al. showed
that the CTL epitope clusters derived from Nef protein
tend to coincide with hydrophobic regions, whereas the
noncluster regions are predominantly hydrophilic [8]. Their
in vitro analysis of the proteasomal degradation products
of HIV-Nef protein demonstrates a differential sensitivity
of cluster and noncluster regions to proteasomal processing
and the cluster regions are digested by proteasomes with
greater preference for hydrophobic P1 residues. But the
authors admitted that some cytosolic endoproteases other
than proteasomes may also be involved in the production
o fc e r t a i nN e f - C T Le p i t o p e si nn a t u r a lc o n d i t i o n[ 8]. In
both these studies the primary focus was on one protein
( N e f )i nt h ew h o l eH I Vp r o t e o m e .S os i m i l a rs t u d i e so n
other HIV proteins would certainly be interesting and could
reveal some important feature of the HIV-CTL epitopes.
In contrast to the notion that HIV CTL epitopes are more
conserved and hydrophobic in nature, more recent study
revealed that distribution of CTL epitopes in 99% of the
HIV-1 protein sequences follows a random pattern and is
indistinguishable from the distribution of CTL epitopes in
proteins from other proteomes such as hepatitis C virus
(HCV), influenza and for three eukaryote proteomes. In this
study, the authors opted for the computational approach
to predict the large set of CTL epitopes where proteasome
cleavage pattern, TAP, and HLA-binding, three most
crucial steps in classical endogenous antigen presentation
pathway, were predicted by means of computational tools.
The use of experimentally validated epitopes instead of
computationally predicted epitopes could influence the
outcome of the study and may lead the authors to a different
conclusion. To shed some light on the contradiction of
different studies mentionedabove, an investigationinvolving
hydrophobic and conservancy pattern of experimentally
validated optimal CTL epitopes (Table 2)f r o m5H I V
proteins (gp160, Nef, p17, p24, and RT) was conducted
in this study. Relative conservancy and hydrophobicity
of the five selected HIV proteins were analyzed. 100
proteins sequences of different HIV clades retrieved from
the Uniprot database (http://www.uniprot.org/)w e r e
used as an input for both conservancy and hydrophobic
pattern prediction. To unveil the conservation pattern,
multiple sequence alignment (MAS) was constructed
using well stabled tool called Clustal W version 2.0
(http://www.ebi.ac.uk/Tools/clustalw2/index.html)
developed by European Bioinformatics Institute (EBI).
From the MSA the conservancy score for each amino
acid position was obtained. To predict the hydrophobicity
score Protscale tool of the ExPASy Proteomics Server
(http://www.expasy.ch/tools/protscale-ref.html)a n d
algorithm (developed by Abraham and Leo) previously
used by Lucchiari-Hartz et al. [8] were employed. Both the
hydrophobicity and conservancy scores for each amino
acid position within a particular HIV protein were used
to calculate the total scores for both these parameters.
Figure 3 shows the total hydrophobicity and conservancy
scores of 5 individual HIV proteins in agreement with
previous study [21]. We found that both the RT and p24
are relatively conserved and more hydrophobic than the
rest of the analyzed HIV proteins (Figure 3). To visualize
the overlapping pattern and correlation between the
hydrophobic pattern and epitope clusters for the five selected
proteins, the epitope count/hit and hydrophobicity scores
wereplottedtogetherforeachprotein(Figure 4).Theepitope
hit score for a particular position is the number of alleles
binding to that particular position.
To compare the correlation among hydrophobicity, con-
servancy, and epitope count, correlation coefficient was
calculated among them (Appendix 1). For the calculation of
correlation coefficient, first the standard deviation of each ofAdvances in Virology 13
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Figure 3: Cumulative conservancy (a) and hydrophobicity (b) scores of five individual proteins of HIV-1.
Table 4: Correlation coefficient.
Correlation score HIV-1 proteins
gp160 Nef p17 p24 RT
Epitope hit versus hydrophobicity 0.11 0.27 0.16 0.26 0.12
Epitope hit versus conservancy 0.097 0.21 0.19 0.23 0.047
Hydrophobicity versus conservancy 0.20 0.22 0.23 0.15 0.009
the three score parameters (epitope count, hydrophobicity,
and conservancy) was obtained (Appendix 1). Table 4 shows
the correlation score values among these three parameters.
From the correlation score it was evident that Nef epitope
clusters were strongly correlated with the hydrophobicity
and conservancy. p24 protein also showed relatively high
correlation between epitope clusters and hydrophobicity and
between conservancy and epitope clusters. In contrast, gp160
and RT showed relatively weak yet similar correlation among
the parameters. p17 showed strong correlation when epitope
hit was compared with conservancy but showed moderate
correlation between epitope hit and hydrophobicity. So these
findings suggested that not all the epitopes of HIV proteome
are derived from conserved and hydrophobic regions of
HIV-1 proteome although this hypothesis was found to be
validfortwoofthefiveHIVproteins(Nefandp24)asbothof
theseproteinsshowedasignificantcorrelationamongepitope
cluster, hydrophobicity, and conservancy. But the very weak
correlationobtainedforgp160andRTdiminishedthegeneral
applicability of the hypothesis that all the HIV CTL epitopes
were conserved and hydrophobic in nature.
5. The Role of MHC Class I on
Immune Control of HIV Infection
Significant variation in the susceptibility to HIV-1 infection
a n de s p e c i a l l yi nt h ec l i n i c a lo u t c o m ea ft e ri n f e c t i o ni s
observed in HIV infected patients. For instance, variation in
the level of circulating virus particles in the plasma during
thenonsymptomaticphaseiscommonlyobservedamongthe
patients [22]. In addition to this, there is evidence that in
certain cases individuals known as long-term nonprogressor
(LTNP), infected with HIV, remain asymptomatic without
antiretroviral therapy (ART) in their life time due to the
slow or arrested evolution of HIV [23]. The most plausible
explanation is that the variation in the susceptibility and
outcome of HIV infection is largely due to host factors and
viral adaptation to selective pressure. Recently Fellay et al.
conducted a whole-genome association study to identify the
host factor associated with control of HIV-1. In this study
they identified two distinct polymorphisms associated with
HLA loci B and C [24]. Surprisingly, almost all HLA class I
polymorphisms were found to occur in those residues that
belong to peptide-binding groove of these molecules thereby
determining the epitopes that bind to each HLA molecule
[25]. Among the three MHC class I loci in humans (HLA-
A, HLA-B, and HLA-C), HLA-B is the most polymorphic,
compared with HLA-A and HLA-C molecules (IMGT/HLA
database:http://www.ebi.ac.uk/imgt/hla/).Amoredirectevi-
dence of the association between HLA polymorphism and
d i s e a s ep r o g r e s s i o ni nH I Vi n f e c t e di n d i v i d u a lc a m ef r o ma
previous study where they showed HLA-B
∗3503 associated
with rapid disease progression differs in only one amino
acid from HLA-B
∗3501 for which no such association was
observed [26]. The presence of HLA-B
∗57 allele in a large
proportion of LTNPs signifies its role in controlling disease
progression and mutations in HLA-B
∗57-restricted Gag epi-
topes were frequently present in all viruses from plasma but
interestingly inspite of this CTL escape mutations LTNPs
can maintain viral suppression [27, 28]. The escape mutation
in the HLA-B
∗57-restricted Gag epitopes can be considered
as a consequence of strong evolutionary pressure exerted
by the host immune response. Previous studies showed
that although mutation in the conserved gag p24 epitope
DRFYKTLRAEhelpsthevirustoevadeCTLresponse,italso
impairs its ability to replicate because the mutation occurs in
a very conserved position which is functionally constrained
[29]. Among the three HLA class I molecules, HLA-B is
considered as the most important factor for restricting HIV
diseases progression and T cells responding to HLA-B-
restricted epitopes appear to be immunodominant [30, 31].14 Advances in Virology
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Figure 4: Epitope clusters and hydrophobic pattern of five HIV proteins. The 𝑋-axis represents the amino acid position. The primary 𝑌-axis
(left) shows the hydrophobicity scores whereas the secondary 𝑌-axis (right) represents the epitope hit/count values. The blue bars indicate
the hydrophobicity score whereas the red line represents the epitope hit values. For the hydrophobicity scores, the negative values were not
s h o w ni nt h efi g u r e ,a n do n l yt h es c o r e sg r e a t e rt h a n0w e r ep l o t t e d .
Moreover, detailed study of the CTL epitopes in whole HIV-1
proteome revealed that HLA-B-restricted epitopes are more
conserved compared to epitopes restricted by HLA-A and
C. The same study also showed that although for most of
t h ep r o t e i n st h ef r a c t i o n so fu n i q u eH L A - Aa n dBr e s t r i c t e d
positions are equivalent in the total HIV clade-B proteome,
G a g - p 2 4a n dN e fs e e m e dt ob ep r e f e r e n t i a l l yt a r g e t e db y
HLA-B alleles as the B-restricted fractions were found to be
over threefold higher than the A-restricted residues [32].
In our study, the analysis of different class I HLA alleles
that recognize all the listed CTL optimal epitopes revealed
some interesting features of HLA restriction patterns of
HIV-1 CTL epitopes. Figure 5 shows the number of optimum
epitopes recognized by 62 different class I HLA alleles. It was
found that HLA-B
∗57 was the most successful as far as the
numberofepitoperecognitionwasconcernedasitrecognizes
22 different optimal epitopes. The other successful HLA
alleles were HLA-A
∗3, A
∗2, B
∗7, A
∗11, and B
∗35 (Figure 5).
Among the total HLA alleles HLA-B contributes to the 50%
of the total allele pool whereas HLA-A and C constitute 27%
and 23%, respectively (Table 5).
These data also support the previous findings and also
signify the role of HLA-B alleles in controlling HIV-1 infec-
tion as HLA-B was found to be associated with the 60%
of the experimentally validated CTL epitopes. In harmony
with the finding of Costaa et al. [32]w ea l s oo b s e r v e da
low % (9% of the total optimal epitope pool) of epitopes
was recognized by HLA-C alleles. We have also analyzed
the % of the epitopes associated with HLA-A and B alleles
in individual HIV proteins (gp160, Nef, p24, p17, and RT).Advances in Virology 15
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Figure 5: The number of unique alleles recognized by the optimal CTL epitopes.
Table 5: Analysis of the different HLA alleles.
HLA
Total number
and as % of total
HLAs
Number of
epitope
recognized
%o fe p i t o p e
recognized by HLA in
total epitope pool
A1 7 ( 2 7 % ) 8 6 3 1 %
B 31 (50%) 165 60%
C 14 (23%) 24 9%
Analysis showed that only the p24 and Nef epitopes were
associated with higher numbers of HLA-B alleles than A
alleles.Incontrast,epitopesderivedfromgp160,p17,protease,
and other proteins (Tat, Rev, Vpu, Vpr, Vif) were recognized
by slightly greater number of A alleles compared to B alleles.
In case of intergrase, the epitopes were restricted by almost
similar number of A and B alleles. There was a significant
difference between the HLA
∗Aa n dH L A
∗Ba s s o c i a t e de p i -
topes for RT and p24. For RT the % of HLA
∗Aa n dH L A
∗B
associatedepitopesare19and6.28,respectively.Incaseofp24
the % of HLA
∗B associated epitopes are significantly higher
(20%) than the HLA
∗A epitopes (3.5%).
6. Conclusion
As CTL response against HIV infected cells is proved
t ob ec r u c i a li nc o n t r o l l i n gv i r u sp o p u l a t i o ni nt h eh o s t ,
r a t i o n a l l yt h eC T Lb a s e dv a c c i n es h o u l dh a v eap r o f o u n d
effect on HIV infection. Yusim et al. suggested that epitope
clustering methods provide an alternative strategy to design
novel multiepitope vaccine. They also suggested that the
multiepitope vaccine should not be composed of a string
of single epitopes, rather it should be composed of short
region containing the epitope clusters and proximal regions
flanking the epitope cluster that may be essential for optimal
processingofepitopes.Theseepitopeclustersharbormultiple
overlapping epitopes which may be recognized by multiple
H L Aa l l e l e s .I nc o n c l u s i o n ,t h i ss t u d yh a ss h o w nt h ea n a l y s i s
of the HIV-1 CTL epitopes which revealed that Nef and
p24 proteins of HIV-1 can be considered for CTL based
multiepitope vaccine design since a significant number of
optimal CTL epitopes are derived from Nef and Gag-p24
a n da l m o s ta l lt h e s ee p i t o p e ss h o w e dac l u s t e r i n gp a t t e r n .
A further study is needed to test these proposed vaccine
candidates in laboratory animal to test safety and immunity
against HIV.
Appendix
CorrelationbetweenDifferentScores.Therearethreescoresfor
each of the 𝑘-th position of epitope:
(a) epitope hit score: EHS(𝑘),
(b) hydrophobicity score: HS(𝑘),
(c) conservancy score: CS(𝑘).
Let us assume that the position range of epitope, for which
each of scores exists, is 𝑗 to 𝑛.
Now
( a )t h ea v e r a g ee p i t o p eh i ts c o r eE H SAVG = (1/(𝑛 − 𝑗 +
1))∑
𝑛
𝑘=𝑗 EHS(𝑘);
(b) the average hydrophobicity score HS AVG = (1/(𝑛 −
𝑗+1 ) )∑
𝑛
𝑘=𝑗 HS(𝑘);
(c) the average conservancy score CS AVG = (1/(𝑛 − 𝑗 +
1))∑
𝑛
𝑘=𝑗 CS(𝑘).
Now
( a )t h es t a n d a r dd e v i a t i o no fe p i t o p eh i ts c o r e
EHS SD =
1
𝑛−𝑗+1
𝑛
∑
𝑘=𝑗
(EHS(𝑘) − EHS AVG)
2. (A.1)
(b) The standard deviation of hydrophobicity score
HS SD =
1
𝑛−𝑗+1
𝑛
∑
𝑘=𝑗
(HS(𝑘) − HS AVG)
2. (A.2)16 Advances in Virology
( c )Th es t a n d a r dd e v i a t i o no fc o n s e rv a n c ys c o r e
CS SD =
1
𝑛−𝑗+1
𝑛
∑
𝑘=𝑗
(CS(𝑘) − CS AVG)
2. (A.3)
Then the correlation coefficient between the scores are
calculated as below.
Correlation between epitope hit count and hydrophobic-
ity score
Corr(EHS,HS)
=
∑
𝑛
𝑘=𝑗 (EHS(𝑘) − EHS AVG)(HS(𝑘) − HS AVG)
(𝑛 − 𝑗)EHS SD × HS SD
.
(A.4)
Correlationbetweenepitopehitcountandconservancyscore
Corr(EHS,CS)
=
∑
𝑛
𝑘=𝑗 (EHS(𝑘) − EHS AVG)(CS(𝑘) − CS AVG)
(𝑛 − 𝑗)EHS SD × CS SD
.
(A.5)
Correlation between conservancy and hydrophobicity score
Corr(CS,HS)
=
∑
𝑛
𝑘=𝑗 (CS(𝑘) − CS AVG)(HS(𝑘) − HS AVG)
(𝑛 − 𝑗)CS SD × HS SD
.
(A.6)
Th ec a l cul a ti o no fea c ho fth e sec o rr e l a ti o n si sc a rri e do u tf o r
each protein group separately.
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